Breast cancer and pregnancy: How safe is trastuzumab?

Nature Reviews Clinical Oncology

Volumn 6, Issue 6, 2009, Pages 367-370

  Azim, Hatem A ^a   Peccatori, Fedro A ^a   Liptrott, Sarah J ^a   Catania, Chiara ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ADULT; AMENORRHEA; ANAMNESIS; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TEST; PRIORITY JOURNAL; TREATMENT DURATION; BREAST TUMOR; METABOLISM; MULTIMODALITY CANCER THERAPY; PREGNANCY COMPLICATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 68549135367     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.48     Document Type: Article

References (17)

1. Azim, H. & Azim, H. A. Jr Targeting Her-2/neu in breast cancer: As easy as this! Oncology 74, 150-157 (2008).
2. Berkowitz, G. S., Skovron, M. L., Lapinski, R. H. & Berkowitz, R. L. Delayed child-bearing and the outcome of pregnancy. N. Engl. J. Med. 322, 659-664 (1990).
3. Koren, G., Pastuszak, A. & Ito, S. Drugs in pregnancy. N. Engl. J. Med. 338, 1128-1137 (1998).
4. Leyland-Jones, B. dose-scheduling - Herceptin. Oncology 61 (Suppl. 2), 31-36 (2001).
5. Watson, W. J. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet. Gynecol. 105 642-643 (2005).
6. Fanale, M. A., Uyei, A. R., Theriault, R. L., Adam, K. & Thompson, R. A. treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin. Breast Cancer 6, 354-356 (2005).
7. Waterston, A. M. & Graham, J. Effect of adjuvant trastuzumab on pregnancy. J. Clin. Oncol. 24, 321-322 (2006).
8. Bader, A. A., Schlembach, D., Tamussino, K. F., Pristauz, G. & Petru, E. Anhydramnios associated with adminstration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol. 8 79-81 (2007).
9. Shrim, A., Garcia-Bournissen, F., Maxwell, C., Farine, D. & Koren, G. Favorable pregnancy outcome following trastuzumab (Herceptin®) use during pregnancy. Case report and updated literature review. Reprod. Toxicol. 23, 611-613 (2007).
10. Sekar, R. & Stone, P. R. Trastuzumab use for metastatic breast cancer in pregnancy. Obstet. Gynecol. 110, 507-510 (2007).
11. Witzel I. D., Müller, V., Harps, E., Janicke, F. & Dewit, M. Trastuzumab is pregnancy associated with poor fetal outcome. Ann. Oncol. 19, 191-192 (2008).
12. Berveiller, P., Mir, O., Sauvanet, E., Antoine, E. C. & Goldwasser, F. ectopic pregnancy in a breast cancer patient receiving trastuzumab. Reprod. Toxicol. 25, 286-288 (2008).
13. Pant, S., Landon, M. B., Blumenfeld, M., Farrar, W. & Shapiro, C. L. Treatment of breast cancer with trastuzumab during pregnancy. J. Clin. Oncol. 26, 1567-1569 (2008).
14. Weber-schoendorfer, C. & Schaefer, C. Trastuzumab exposure during pregnancy. Reprod. Toxicol. 25, 390-391 (2008).
15. Perez, E. A. Cardiac toxicity of ErbB2-targeted therapies: What do we know? Clin. Breast Cancer 8 (Suppl. 3), S114-S120 (2008).
16. Sliwa, K., Fett, J. & Elkayam, U. Peripartum cardiomyopathy. Lancet 368, 687-693 (2006).
17. Negro, A., Brar, B. K. & Lee, K. F. Essential roles of Her2/erbB2 is cardiac development and function. Recent Prog. Horm. Res. 59 1-12 (2004). Diagnosis. Unintended pregnancy during adjuvant trastuzumab therapy. Management. Cessation of trastuzumab and close monitoring of mother and fetus during pregnancy.